News
Follow the latest news on Bioqube Ventures, the Bioqube Factory Fund and our portfolio companies here.
Follow the latest news on Bioqube Ventures, the Bioqube Factory Fund and our portfolio companies here.
14/04/2025
DUBLIN, Ireland and OXFORD, United Kingdom, April 14, 2025 (GLOBE NEWSWIRE) — SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing of emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to emactuzumab for the treatment of TGCT patients […]
01/04/2025
Newly Appointed Board Chair, Philip Astley-Sparke, Brings Transatlantic Late-Stage Development, Regulatory and Commercial Expertise Strengthened Leadership and Expanded U.S. Presence Positions SynOx for Regulatory Filings and Commercialization of Emactuzumab for Tenosynovial Giant Cell Tumours (TGCT) DUBLIN, IRELAND and OXFORD, UK, April 1, 2025 – SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing of […]
17/03/2025
Egle Therapeutics receives significant non-dilutive funding to accelerate the clinical development of its lead immuno-oncology therapeutic candidate, EGL-001, as part of the “Innovations in Biotherapies and Bioproduction” call for projects under the French government’s France 2030 initiative. PARIS–(BUSINESS WIRE)– Egle Therapeutics, a clinical-stage biotechnology company developing therapies targeting regulatory T cells (Tregs) for immuno-oncology and […]
28/01/2025
Aarhus, Denmark, 28 January 2025, Commit Biologics (“Commit”), a pioneer in the activation of the complement system to treat cancer and autoimmune disease, today announces a €5.5m extension to its seed financing. The contribution from new investor Korys brings the total seed financing raised since Commit’s launch to €21.5m. Commit emerged from stealth last May, […]
22/01/2025
Brussels, Belgium, January 9, 2025 – Spica Therapeutics (“Spica”), a pioneering biotech company focused on macrophage biology, today announced its emergence from stealth mode, supported by Bioqube Ventures. Headquartered in Belgium, with a site in Denmark, Spica is developing a proprietary platform technology to selectively target macrophage subsets. The company’s initial focus includes two lead […]
13/01/2025
Paris, France, January 13, 2025 – Egle Therapeutics, a clinical-stage biotechnology company advancing the next generation of regulatory T cell (Treg)-focused therapies for oncology and autoimmune diseases, today announced the appointment of experienced biotechnology industry executive, Christophe Quéva, Ph.D., as Chief Executive Officer (CEO). With over 20 years of experience in the biotechnology industry, Dr. […]
09/01/2025
Munich, Germany and San Francisco, USA, January 09, 2025 – CatalYm today announced the appointment of Scott Clarke as Chief Executive Officer. Mr. Clarke brings over two decades of executive leadership experience in driving company growth, developing products, and shaping and executing transactions in the biopharmaceutical industry. He takes the helm as CatalYm enters a new stage of […]
08/01/2025
Aarhus, Denmark, 8 January 2025 – Commit Biologics (“Commit”), a pioneer in the activation of the complement system to treat cancer and autoimmune disease, today announces the appointment of Janine Schuurman, Ph.D. to its Board of Directors. Dr Schuurman is a widely recognized scientific leader with over 25 years’ experience in antibody research, discovery, and development. […]
30/10/2024
Gilde Healthcare Leads Series B Extension, Joining Premier Syndicate of Leading Life Science Investors Funding Supports Registrational Phase 3 TANGENT Trial of Emactuzumab, a Best-in-Class CSF-1 Receptor Targeted Antibody, for the Treatment of Tenosynovial Giant Cell Tumour TANGENT Study Underway with First Patients Dosed DUBLIN, IRELAND and OXFORD, UK, October 30, 2024 – SynOx Therapeutics Limited […]
15/10/2024
Aarhus, Denmark, 15 October 2024 – Commit Biologics (“Commit”), a pioneer in the activation of the complement system to treat cancer and autoimmune disease, today announces the appointment of Mikkel Wandahl Pedersen as Chief Scientific Officer (CSO). Dr Pedersen is a seasoned R&D executive and scientific leader with over two decades of experience in immuno-oncology and […]
09/10/2024
Leiden, The Netherlands – October 9, 2024 – Anavo Therapeutics, a global leader in unlocking the full therapeutic potential of phosphatase biology, today announced the appointment of Edward Holson, Ph.D., as Chief Scientific Officer (CSO). Based in Boston, he will also serve as President of Anavo US, overseeing R&D operations both in the US and Europe. […]
16/09/2024
BOSTON, Sept. 16, 2024 (GLOBE NEWSWIRE) — Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies for patients with solid tumors, today announced the closing of its initial public offering of 20,125,000 shares of its common stock at a public offering price of $18.00 per share, which includes 2,625,000 […]
15/08/2024
BOSTON, Mass., August 15, 2024 – Bicara Therapeutics, a clinical-stage biotechnology company developing transformative bifunctional therapies for patients with solid tumors, today announced the appointments of Mike Powell, Ph.D., and Christopher Bowden, M.D., to the company’s board of directors. Dr. Powell currently serves as executive partner of Omega Funds and will serve as Bicara’s chairman of […]
16/07/2024
Munich, Germany, July 16, 2024 – CatalYm today announced the completion of a $150 million Series D financing. The oversubscribed round was led by new investors, Canaan Partners and Bioqube Ventures, and joined by Forbion’s Growth Opportunities Fund (“Forbion Growth”), Omega Funds and Gilde Healthcare. Existing investors Jeito Capital, Brandon Capital Partners, Novartis Venture Fund […]
27/06/2024
First-in-class bifunctional EGFR/TGF-β inhibitor, ficerafusp alfa, in combination with pembrolizumab has demonstrated clinically meaningful anti-tumor activity and significant improvement over standard of care in HNSCC with at least 12 months of follow-up In HPV-negative HNSCC, data demonstrated an 64% ORR, 18% CR rate and mPFS of 9.8 months; median duration of response and median overall […]
15/05/2024
Cambridge, UK, 15 May 2024: Enhanc3D Genomics, a company developing disruptive technologies to unlock the 3D genome for use in novel target identification and unique patient stratification, today announced the appointment of Hazel Jones as Chief Executive Officer, after a successful six-month tenure as interim CEO and COO. As COO and interim CEO Hazel has overseen […]
10/05/2024
Paris, France, May [date], 2024 – EGLE Therapeutics, a clinical-stage biotechnology company uniquely positioned to advance the next generation of regulatory T cell-focused therapies for oncology and auto-immunity, announced today the appointment of Pejvack Motlagh MD, MSc, as Chief Medical Officer and John Celebi, as Independent Board Member. “We are excited to welcome Pejvack and […]
09/05/2024
Aarhus, Denmark – 9 May 2024 – Commit Biologics (“Commit”), a pioneer in the activation of the complement system to treat cancer and autoimmune disease, today exits from stealth with €16m in seed funding from Bioqube Ventures and Novo Holdings. Commit plans to accelerate development of its Bispecific Complement Engaging (BiCE™) platform, which uses single […]
30/04/2024
• SynOx is developing emactuzumab – a potential best-in-class, next-generation CSF1(R) inhibiting monoclonal antibody • Provides flexible loan facility to support additional clinical work and activities to drive its successful registration and commercialisation • Funding is additional to recent $75m Series B financing Dublin, Ireland and Oxford, UK, 30 April 2024: SynOx Therapeutics Limited (“SynOx” […]
22/04/2024
Dublin, Ireland and Oxford, UK, 22 April 2024: SynOx Therapeutics Limited (“SynOx” or the “Company”), the late-stage clinical biopharmaceutical company, is pleased to announce the close of a $75m Series B financing. The financing was co-led by Forbion, HealthCap and new investor Bioqube Ventures. The proceeds will be used to generate registrational Phase 3 clinical […]
04/04/2024
April 04, 2024 03:30 PM Eastern Daylight Time Egle Therapeutics to present novel immunocytokine preclinical data for EGL-001 with poster presentation at the 2024 AACR Annual Meeting In the poster, entitled “EGL-001 is a novel immunocytokine designed to specifically target and disarm T regulatory cells in the tumor microenvironment”. Egle scientists present evidence that EGL-001, […]
26/03/2024
BOSTON, Mass., March 26, 2024 – Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable immune response, today announced the appointments of Jeltje Schulten, M.D., MBA, as SVP of clinical and medical affairs and Rita Dalal, MBBS, MPH, as vice president of clinical development. “With our first-in-class EGFR/TGF-β-trap bifunctional antibody, […]
20/03/2024
– PRTX007 program to support DTRA’s efforts to establish biological defense solution against Lassa fever and other hemorrhagic viruses – SAN DIEGO, March 20, 2024 – Primmune Therapeutics, a biotech company harnessing the power of the innate immune system, today announced that it was awarded a $22,480,552 contract by the Defense Threat Reduction Agency (DTRA) […]
31/01/2024
Appointment forms part of ongoing plans for continued development of the GenLink3D genomics platform and formation of strategic commercial and academic partnerships Cambridge, UK, 31 January 2024 – Enhanc3D Genomics, a company developing disruptive technologies to unlock the 3D spatial genome for target and biomarker discovery, today announced the appointment of Dr Daniel Turner as Chief Scientific […]
12/12/2023
Proceeds to accelerate clinical development of first-in-class bifunctional EGFR/TGF-β inhibitor, BCA101, for multiple cancer types, including 1L HPV-negative recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) Presented positive interim clinical data at 2023 ASCO Annual Meeting and ESMO Congress 2023 from ongoing Phase 1/1b dose expansion study of BCA101 in combination with pembrolizumab demonstrating […]
23/10/2023
First-in-class bifunctional EGFR/TGF-β inhibitor, BCA101, in combination with pembrolizumab continues to demonstrate clinically meaningful preliminary anti-tumor activity consistent with previous results BOSTON, Mass., October 23, 2023 – Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable immune response, today announced the presentation of updated, positive interim data from its ongoing, […]
16/10/2023
Boston, Mass., October 16, 2023 – Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable immune response, today announced the expansion of its board of directors with the appointments of biopharmaceutical industry veterans Kate Haviland and Scott Robertson. “Kate and Scott bring an impressive breadth of experience and leadership within […]
11/10/2023
SAN DIEGO, October 11, 2023 – Primmune Therapeutics, a biotech company harnessing the power of the innate immune system, today announced the upcoming presentation of new clinical data from its Phase 1 study of PRTX007, an orally administered prodrug of a novel, small molecule toll-like receptor 7 (TLR7)-specific agonist, at the 2023 American Association for […]
21/09/2023
The company appoints industry veteran Shaun McNulty as Chief Scientific Officer and welcomes R&D expert Anna Quattropani as Senior Vice President of Chemistry & Non-Clinical Development Leiden, The Netherlands – September 21, 2023 – Anavo Therapeutics, a global leader in unlocking the full therapeutic potential of phosphatase biology, announced the appointment of Shaun McNulty, DPhil, […]
25/07/2023
CAMBRIDGE, Mass., July 24, 2023 – Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable immune response, today announced the appointment of David Raben, M.D., as chief medical officer. Dr. Raben joins Bicara with more than 25 years of biopharma and academic translational oncology experience, having most recently served as […]
05/06/2023
Phase 1/1b results to be highlighted in an oral presentation at 2023 ASCO Annual Meeting CAMBRIDGE, Mass., June 5, 2023 – Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable immune response, today will present positive interim data from its ongoing, open-label Phase 1/1b dose expansion study of BCA101, a […]
02/05/2023
Leiden, The Netherlands, and Heidelberg, Germany, May 2, 2023 – Anavo Therapeutics, a global leader in unlocking the full therapeutic potential of human phosphatase biology, announced today an EUR 8.5 million seed round extension, adding MRL Ventures Fund as a new investor. All existing investors, M Ventures, INKEF, Taiho Ventures, and Bioqube Ventures, participated in the […]
18/04/2023
— PRTX007 was shown to be well-tolerated with a favorable safety profile for all analyzed cohorts in the Phase 1 study — — Stable systemic immune induction was observed in the 750mg cohort, with CD8+ T cells and NK cell activation significantly increasing from pretreatment to end of dosing in all healthy volunteers (HVs) — — No […]
14/03/2023
SAN DIEGO, March 14, 2023 – Primmune Therapeutics, a biotech company harnessing the power of the innate immune system to treat solid tumors in the advanced cancer setting and for the clearance of human papillomavirus and related pre-cancerous cervical lesions, today announced the upcoming presentation of new clinical data from its Phase 1 study of […]
06/03/2023
Financing will support future studies of lead program BCA101, currently in Phase 1/1b clinical development in head and neck cancer, and pipeline growth Financing co-led by Red Tree Venture Capital and RA Capital Management CAMBRIDGE, Mass., MARCH 6, 2023 — Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable […]
20/10/2022
GenLink3DTM provides the first high-resolution mapping of DNA interactions in 3D space, enabling the vast array of non-coding genetic variations to be deciphered into actionable disease biomarkers and treatment targets Funds will be used to rapidly generate deep datasets of novel diagnostic signatures and candidate therapeutic targets across multiple immune-related diseases for internal and external […]
15/09/2022
Financing led by Pureos Bioventures with significant participation from new and historical investors Funds will primarily be used to identify candidates to develop, conduct IND-enabling studies and further build the organization Tridek-One also appointed Laurence de Schoulepnikoff as chief executive officer and Erik van den Berg as chairman of the board of directors Paris, France, […]
26/05/2022
Awarded grant funding from Johnson & Johnson Innovation and one year of JLABS residency Functional genomics technology focused on the uncharted non-coding regions across the whole human genome Identification of 3D genetic interactions that are disease-associated to revolutionise target and biomarker identification Unique GenLink3DTM platform opens new opportunities for multiOMICs data integration in patient samples […]
30/11/2021
The five-year services agreement provides for the development and manufacturing of biologics and small molecules for portfolio companies of Bioqube Ventures The offering will accelerate timelines for the development and manufacturing of molecules and disruptive technologies, Lonza to support Bioqube Ventures with investment de-risking and providing development and manufacturing of drug substance and drug product […]
04/11/2021
SAN DIEGO, November 4, 2021 – Primmune Therapeutics today announced that it has received $8.4 million in a second tranche of the Company’s Series A financing. The total proceeds for the equity raised in the Series A was $31.4 million. These funds will be used to support the further clinical development of PRTX007 as a […]
02/11/2021
SAN DIEGO, November 2, 2021 – Primmune Therapeutics today announced interim results from its Phase 1 study in healthy volunteers with PRTX007, a novel orally-administered, small molecule toll-like receptor 7 (TLR7) specific agonist for acute viral diseases, including SARS-CoV-2, and cancer. This double blind, placebo-controlled Phase 1 study is evaluating the safety, pharmacokinetics (PK), pharmacodynamics […]
26/10/2021
LSP and Bpifrance, through its InnoBio 2 Fund, co-led international investor syndicate Egle Therapeutics SAS (Egle), an emerging biotechnology company focused on developing First-In- Class immunotherapies targeting immune suppressor regulatory T-cells (Tregs) for oncology and autoimmune diseases, today announces that it has completed a €40M ($46.4M) Series A financing. The Series A was co-led by […]
16/08/2021
Leiden, The Netherlands, and Heidelberg, Germany, August 16, 2021 – Anavo Therapeutics, a global leader in unlocking the full therapeutic potential of human phosphatase biology, today announced that the company has partnered with BioLabs Global, a developer and operator of premium co-working laboratories in the U.S. and Europe, to establish its R&D center as one of […]
24/06/2021
Karl-Heinz Altmann, Andrew Mortlock and Gregg Siegal to join Anavo’s SAB Leiden, The Netherlands, June 24, 2021 – Anavo Therapeutics, a global leader in unlocking the full therapeutic potential of human phosphatase biology, today announced three key appointments to its Scientific Advisory Board in the persons of Karl-Heinz Altmann, currently Full Professor of Pharmaceutical Sciences […]
22/04/2021
Anavo Therapeutics Launches with EUR 20 Million Seed Financing to Create Industry-Leading Pipeline of Allosteric Phosphatase Modulators
09/03/2021
SAN DIEGO, February 5, 2021 – Today, Primmune Therapeutics announced the appointment of Rich Daniels as Chief Operating Officer, Scott Zook as Senior Vice President, Global Manufacturing and Randy Adams as Senior Advisor, Commercial Development. “The appointments of Rich, Scott and Randy to the team build on the recent close of our Series A financing to support the […]
12/01/2021
SAN DIEGO, January 12, 2021 – Today, Primmune Therapeutics announced the close of its Series A financing round with the addition of $4.0 million from Bioqube Ventures, a European life sciences venture capital firm. This brings the total of the Series A financing raise to $31.4 million. These funds will be used to support the development of PRTX007, […]
24/09/2020
Brussels/Hasselt, Belgium – 24th September 2020 – Bioqube Ventures, a European life sciences venture capital firm, today announces that Tom Heyman joins Bioqube Ventures as Operating Partner and Peter Verhaeghe will chair the LP and Advisory Committee of the Bioqube Factory Fund I. Bolstering the team with industry veterans Tom Heyman and Peter Verhaeghe will […]
10/06/2020
Bioqube Ventures announces today the first closing of Bioqube Factory Fund I, a new early stage venture capital fund focused on the development of therapeutic assets and technology platforms in Europe.